Nanotechnology has brought about the advent of personalized medicine in the era of targeted
therapeutic strategies for cancer therapy. The ability to exploit tumor features for therapeutic gain has made it
possible to manufacture more effective nanomedicines for cancer treatment. However, known obstacles, including
the inability to overcome pathophysiological barriers of tumors, have impeded disease management. In spite of
this, recent efforts have been made to develop more functionalized nanosystems that utilize the active-targeting
approach. This article reviews the FDA-approved cancer drug delivery systems in the general framework of
personalized nanomedicine. We discuss the latest efforts in the development of functionalized nano-systems, and
summarize relevant ongoing preclinical and clinical trials.
Keywords: Personalized medicine, cancer therapy, drug delivery, nanoparticles, tumor-targeted nanomedicines, nanotechnology.
Rights & PermissionsPrintExport